skip to main content

Minor Bleeding on DOAC Management — EECC MCQ

Instant feedback + full explanation. One question, done properly.

ModerateCardiac PharmacologyMinor Bleeding on DOAC ManagementEECC

A 55-year-old man with AF on apixaban presents to the emergency department after a fall with loss of consciousness. He has a laceration on his forehead but is neurologically intact (GCS 15). His apixaban dose was taken 4 hours ago. An anti-Xa level is measured at 250 ng/mL (therapeutic). Is specific DOAC reversal needed?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — For minor bleeding without haemodynamic instability or critical-site haemorrhage, specific DOAC reversal is NOT needed — local haemostatic measures (wound closure, pressure) and temporary DOAC interruption (skip 1-2 doses) are sufficient; reversal agents are reserved for life-threatening or critical-site bleeding

DOAC-related bleeding management is stratified by severity per the ESC 2024 AF Guidelines and EHRA guidance: (1) Minor bleeding (skin lacerations, epistaxis, minor GI): local haemostatic measures (pressure, suturing), skip 1-2 DOAC doses, resume when bleeding stops; (2) Major non-life-threatening bleeding: withhold DOAC, consider tranexamic acid, specific reversal agents NOT routinely needed; (3) Life-threatening or critical-site bleeding (intracranial, pericardial, retroperitoneal, or causing haemodynamic instability): specific reversal — andexanet alfa for factor Xa inhibitors (apixaban, rivaroxaban), idarucizumab for dabigatran; (4) Four-factor PCC may be used as an alternative when specific reversal agents are unavailable. Anti-Xa levels can help confirm drug presence/absence but therapeutic-range levels do NOT mandate reversal unless bleeding is severe.

Reference: ESC (2024): AF Guidelines; EHRA Practical Guide